High bone mass gene of 11q13.3

Abstract

The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

Description

RELATED APPLICATIONS [0001] This application is a continuation-in-part of application Ser. No. 09 / 229,319, filed Jan. 13, 1999, which claims benefit of U.S. Provisional Application No. 60 / 071,449, filed Jan. 13, 1998, and U.S. Provisional Application No. 60 / 105,511, filed Oct. 23, 1998, all of which are herein incorporated by reference in their entirety.FIELD OF THE INVENTION [0002] The present invention relates generally to the field of genetics, genomics and molecular biology. More particularly, the invention relates to methods and materials used to isolate, detect and sequence a high bone mass gene and corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in the ontology and physiology of bone development. The invention also provides nucleic acids, proteins, cloning vectors, expression vectors, transformed ...

AI Technical Summary

Benefits of technology

[0019] The present invention describes the Zmax1 gene and the HBM gene on chromosome 11q13.3 by genetic linkage and mutation analysis. The use of additional genetic markers linked to the genes has aided this discovery. By using linkage analysis and mutation analysis, persons predisposed to HBM may be readily identified. Cloning methods using Bacterial Artificial Chromosomes have enabled the inventors to focus on the chromosome region of 11q13.3 and to accelerate the sequencing of the autosomal dominant gene. In addition, the invention identifies the Zmax1 gene and the HBM gene, and identifies the guanine-to-thymine polymorphism mutation at position 582 in the Zmax1 gene that produces the HBM gene and the HBM phenotype.

Problems solved by technology

Osteoporosis affects men as well as women, and, taken with other abnormalities of bone, presents an ever-increasing health risk for an aging population.

This rapid loss is generally associated with an increase of bone resorption and formation.

However, the resorptive cycle is more dominant and the result is a net loss of bone mass.

The results of osteoporosis are both personally harmful, and also account for a large economic loss due to its chronicity and the need for extensive and long-term support (hospitalization and nursing home care) from the disease sequelae.

Although this therapy frequently is successful, patient compliance is low, primarily due to the undesirable side-effects of chronic estrogen treatment.

This protocol is similar to that which is used in birth control regimens, and often is not tolerated by women because of the side-effects characteristic of progestin.

The use of calcitonin has been somewhat limited, however.

Its effects are very modest in increasing bone mineral density and the treatment is very expensive.

Senile osteoporosis is similar to postmenopausal osteoporosis in that it is marked by the loss of bone mineral density and resulting increase in fracture rate, morbidity, and associated mortality.

Treatment of this disease has not been very satisfactory.

These studies are difficult because bone mass (the phenotype) is a continuous, quantitative, polygenic trait, and is confounded by environmental factors such as nutrition, co-morbid disease, age, physical activity, and other factors.

Also, this type of study design requires large numbers of subjects.

In particular, the results of VDR studies to date have been confusing and contradictory (Gamero et al, J.

Furthermore, the work thus far has not shed much light on the mechanism(s) whereby the genetic influences might exert their effect on bone mass.

While it is well known that peak bone mass is largely determined by genetic rather than environmental factors, studies to determine the gene loci (and ultimately the genes) linked to variation in bone mass are difficult and expensive.

However, genetic linkage studies involving bone mass are hampered by two major problems.

The first problem is the phenotype, as discussed briefly above.

Bone mass is a continuous, quantitative trait, and establishing a discrete phenotype is difficult.

The second problem is the age component of the phenotype.

By the time an individual can be identified as having low bone mass, there is a high probability that their parents or other members of prior generations will be deceased and therefore unavailable for study, and younger generations may not have even reached peak bone mass, making their phenotyping uncertain for genetic analysis.

However, few markers are sufficiently polymorphic as to be informative in all those individuals.

Images